GlaxoSmithKline (NYSE: GSK) announced today that it has re-submitted the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration (FDA).
The re-submission provides an update to the initial application in 2009. The withdrawal of the initial application was not the result of new findings related to safety or efficacy. The update to the submission has not changed the interpretation of the data submitted.
The provision of this update to the European Regulatory authorities is also underway.
Dutasteride is not approved or licensed in the US or Europe to treat or reduce the risk of prostate cancer.
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients